GIP(3-30)NH2 – a tool for the study of GIP physiology

Research output: Contribution to journal › Review › Research › peer-review

Standard

GIP(3-30)NH2 – a tool for the study of GIP physiology. / Lynggaard, Mads Bank; Gasbjerg, Lærke Smidt; Christensen, Mikkel Bring; Knop, Filip Krag.

In: Current Opinion in Pharmacology, Vol. 55, 2020, p. 31-40.

Research output: Contribution to journal › Review › Research › peer-review

Harvard

Lynggaard, MB, Gasbjerg, LS, Christensen, MB & Knop, FK 2020, 'GIP(3-30)NH2 – a tool for the study of GIP physiology', Current Opinion in Pharmacology, vol. 55, pp. 31-40. https://doi.org/10.1016/j.coph.2020.08.011

APA

Lynggaard, M. B., Gasbjerg, L. S., Christensen, M. B., & Knop, F. K. (2020). GIP(3-30)NH2 – a tool for the study of GIP physiology. Current Opinion in Pharmacology, 55, 31-40. https://doi.org/10.1016/j.coph.2020.08.011

Vancouver

Lynggaard MB, Gasbjerg LS, Christensen MB, Knop FK. GIP(3-30)NH2 – a tool for the study of GIP physiology. Current Opinion in Pharmacology. 2020;55:31-40. https://doi.org/10.1016/j.coph.2020.08.011

Author

Lynggaard, Mads Bank ; Gasbjerg, Lærke Smidt ; Christensen, Mikkel Bring ; Knop, Filip Krag. / GIP(3-30)NH2 – a tool for the study of GIP physiology. In: Current Opinion in Pharmacology. 2020 ; Vol. 55. pp. 31-40.

Bibtex

@article{788d94479845451fb5f8cfb84a6a32ac,
title = "GIP(3-30)NH2 – a tool for the study of GIP physiology",
abstract = "Glucose-dependent insulinotropic polypeptide (GIP) is a gut hormone impacting glucose, lipid and bone metabolism through the GIP receptor (GIPR). The GIP system has key species differences complicating the translation of findings from rodent to human physiology. Furthermore, the effects of endogenous GIP in humans have been difficult to tease out due to the lack of a suitable GIPR antagonist. The naturally occurring GIP(3-30)NH2 has turned out to constitute a safe and efficacious GIPR antagonist for rodent and human use. To study GIP physiology, it is recommended to use the species-specific GIP(3-30)NH2 peptide sequence, and for human intravenous infusions, an antagonist:agonist ratio of a minimum of 600 with a 20 min infusion time before the intervention of interest is recommended. Several studies using GIP(3-30)NH2 are coming, hopefully providing new insights into the physiology of GIP, the pathophysiologic involvement of GIP in several diseases and the therapeutic potential of the GIPR.",
author = "Lynggaard, {Mads Bank} and Gasbjerg, {L{\ae}rke Smidt} and Christensen, {Mikkel Bring} and Knop, {Filip Krag}",
year = "2020",
doi = "10.1016/j.coph.2020.08.011",
language = "English",
volume = "55",
pages = "31--40",
journal = "Current Opinion in Pharmacology",
issn = "1471-4892",
publisher = "Elsevier Ltd. * Current Opinion Journals",

}

RIS

TY - JOUR

T1 - GIP(3-30)NH2 – a tool for the study of GIP physiology

AU - Lynggaard, Mads Bank

AU - Gasbjerg, Lærke Smidt

AU - Christensen, Mikkel Bring

AU - Knop, Filip Krag

PY - 2020

Y1 - 2020

N2 - Glucose-dependent insulinotropic polypeptide (GIP) is a gut hormone impacting glucose, lipid and bone metabolism through the GIP receptor (GIPR). The GIP system has key species differences complicating the translation of findings from rodent to human physiology. Furthermore, the effects of endogenous GIP in humans have been difficult to tease out due to the lack of a suitable GIPR antagonist. The naturally occurring GIP(3-30)NH2 has turned out to constitute a safe and efficacious GIPR antagonist for rodent and human use. To study GIP physiology, it is recommended to use the species-specific GIP(3-30)NH2 peptide sequence, and for human intravenous infusions, an antagonist:agonist ratio of a minimum of 600 with a 20 min infusion time before the intervention of interest is recommended. Several studies using GIP(3-30)NH2 are coming, hopefully providing new insights into the physiology of GIP, the pathophysiologic involvement of GIP in several diseases and the therapeutic potential of the GIPR.

AB - Glucose-dependent insulinotropic polypeptide (GIP) is a gut hormone impacting glucose, lipid and bone metabolism through the GIP receptor (GIPR). The GIP system has key species differences complicating the translation of findings from rodent to human physiology. Furthermore, the effects of endogenous GIP in humans have been difficult to tease out due to the lack of a suitable GIPR antagonist. The naturally occurring GIP(3-30)NH2 has turned out to constitute a safe and efficacious GIPR antagonist for rodent and human use. To study GIP physiology, it is recommended to use the species-specific GIP(3-30)NH2 peptide sequence, and for human intravenous infusions, an antagonist:agonist ratio of a minimum of 600 with a 20 min infusion time before the intervention of interest is recommended. Several studies using GIP(3-30)NH2 are coming, hopefully providing new insights into the physiology of GIP, the pathophysiologic involvement of GIP in several diseases and the therapeutic potential of the GIPR.

U2 - 10.1016/j.coph.2020.08.011

DO - 10.1016/j.coph.2020.08.011

M3 - Review

C2 - 33053504

AN - SCOPUS:85092131027

VL - 55

SP - 31

EP - 40

JO - Current Opinion in Pharmacology

JF - Current Opinion in Pharmacology

SN - 1471-4892

ER -

ID: 250214197